

Serial No.: 09/654,328
Docket No.: B0801.70187US00

- 2 -

In the Claims

Please cancel claims 44, 45, 55, 56 and 58.

Please amend claims 1, 16 and 54.

Please add new claims 59 and 60.

Please re-write the claims as follows:

1. (Currently Amended) A method for treating a subject having an inflammatory joint disorder comprising

administering to a subject in need of such treatment a therapeutically effective amount of a cadherin-11 inhibitory agent

wherein the cadherin-11 inhibitory agent is an antibody to cadherin-11 that inhibits binding of cadherin-11 to a cadherin-11 counter-receptor that is a cadherin.

2. (Cancelled)

3. (Original) The method of claim 1, wherein the inflammatory joint disorder is an autoimmune disease.

4. (Cancelled)

5. (Original) The method of claim 1, wherein the cadherin-11 inhibitory agent is administered locally to a synovium of the subject.

6. (Original) The method of claim 1, wherein the cadherin-11 inhibitory agent binds selectively to cadherin-11.

7. - 15. (Cancelled)

Serial No.: 09/654,328
Docket No.: B0801.70187US00

- 3 -

16. (Currently Amended) The method of claim 1, wherein the cadherin-11 counter-receptor is [selected from the group consisting of a cadherin, an integrin, a carbohydrate and an immunoglobulin family member] cadherin-11.

17. – 49. (Cancelled)

50. (Previously Presented) The method of claim 1, wherein the inflammatory joint disorder is chronic synovitis.

51. (Previously Presented) The method of claim 3, wherein the autoimmune disease is rheumatoid arthritis.

52. (Previously Presented) The method of claim 1, wherein cadherin-11 and the cadherin-11 counter-receptor are expressed by separate cells.

53. (Previously Presented) The method of claim 1, wherein cadherin-11 is expressed by a cell selected from the group consisting of a type A synoviocyte, a type B synoviocyte, a synovial derived fibroblast, a synovial membrane lining cell, an osteoblast, a cartilage-derived cell and an invasive pannus-derived cell.

54. (Currently Amended) The method of claim 1, wherein the cadherin-11 counter-receptor is expressed by a [cell selected from the group consisting of a type A synoviocyte, a type B synoviocyte, a synovial derived fibroblast, a synovial membrane lining cell, an osteoblast, a cartilage-derived cell, an invasive pannus-derived cell, a T lymphocyte, a B lymphocyte, a mast cell, a macrophage, a plasma cell, a dendritic cell and a natural killer cell] synoviocyte.

55. – 56. (Cancelled)

Serial No.: 09/654,328
Docket No.: B0801.70187US00

- 4 -

57. (Previously Presented) The method of claim 1, wherein administering is administering systemically.

58. (Cancelled)

59. (New) The method of claim 1, wherein the cadherin-11 counter-receptor is expressed by a type B synoviocyte.

60. (New) The method of claim 1, wherein the cadherin-11 counter-receptor is expressed by an invasive pannus-derived cell.